You are here

Article Text

Article menu
Download PDFPDF
Clinical science
Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity
  1. Yichen Bai1,
  2. Huanjie Nie2,
  3. Shiyu Wei1,
  4. Xiaohe Lu1,
  5. Xiaoyun Ke1,
  6. Xuejun Ouyang3,
  7. Songfu Feng1
  1. 1 Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, China
  2. 2 Department of Gynecology, Liwan Chinese Traditional Medicine Hospital, Guangzhou, China
  3. 3 Department of Pediatrics, Zhujiang Hospital, Southern Medical University, Guangzhou, China
  1. Correspondence to Dr Songfu Feng, Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China; fsf516{at}163.com

Abstract

Background To evaluate the safety and efficacy of intravitreal conbercept (IVC) injection in the treatment of retinopathy of prematurity (ROP).

Methods Patients with ROP who underwent IVC injection in Zhujiang Hospital from June 2015 to July 2016 were studied retrospectively. The primary outcome was defined as the regression of plus disease. The secondary outcomes were defined as the presence of recurrence, number of injections and the final regression of disease.

Results A total of 48 eyes of 24 patients with ROP were included. Among them, 9 eyes of 5 patients had zone I ROP, 35 eyes of 18 patients had zone II ROP and 4 eyes of 2 patients had aggressive posterior ROP. The mean gestational age was 28.5±1.6 weeks, the mean birth weight was 1209.6±228.6 g, the mean postmenstrual age of first injection was 34.2±1.9 weeks and the mean follow-up period was 31.0±4.7 weeks. Forty of 48 eyes (83.3%) received IVC only once, and the regression of plus disease occurred at an average of 3.5±1.5 weeks after the first injection of conbercept. For eight recurrent eyes (16.7%), four eyes received a second IVC and the remaining four eyes received laser photocoagulation, and the regression of plus disease occurred in 3 weeks. No lens opacity, vitreous haemorrhage, entophthalmia or retinal detachment was observed during follow-up.

Conclusion IVC injection is an effective treatment for ROP.

  • retinopathy of prematurity (ROP)
  • anti-VEGF agents
  • intravitreal conbercept injection

https://doi.org/10.1136/bjophthalmol-2017-311662

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • YB and HN contributed equally.

    • Contributors SF designed this study and did the injection and scanning work with XK. YB and HN contributed equally to the data collection and the draft of this article. SW analysed the data of this study under the direct supervision of XL. XO gave the pediatric diagnosis for the included patients with ROP. 

    • Funding This study was supported by the National Nature Science Foundation of China (81500722). 

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval Ethics Committee of Zhujiang Hospital, Southern Medical University.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Linked Articles

    • At a glance
      Highlights from this issue
      Keith Barton James Chodosh Jost B Jonas
      British Journal of Ophthalmology 2019; 103 i-ii Published Online First: 22 Mar 2019. doi: 10.1136/bjophthalmol-2019-314158